Ironwood Pharmaceuticals Inc (IRWD, Financial) is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is committed to advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. Ironwood Pharmaceuticals Inc explores collaborative licenses, commercial agreements, and acquisition investment as potential growth strategies to expand its research, development, manufacturing, and marketing capabilities.
Stock Performance Overview
As of the latest data, Ironwood Pharmaceuticals Inc (IRWD, Financial) has an outstanding share count of 156.03 million. Institutional ownership stands at 98.77 million shares, making up 63.3% of the total shares. Meanwhile, insiders hold 9.27 million shares, accounting for 5.94% of the total share count.
Ironwood Pharmaceuticals Inc experienced a decline of about 2.2% in its stock value over the past week. As of Oct 05 2023, the stock rose by 0.62%, contrasting with its three-month return of -6.51. A closer look reveals fluctuations in its market cap, which rose to $1.66 billion in the most recent quarter from $1.63 billion in the preceding one. This volatility has sparked keen interest in the company's ownership trends.
Income Breakdown
Institutional Ownership and Key Players
Ironwood Pharmaceuticals Inc's institutional ownership history reveals the levels of trust and confidence that major players have in the company's future. As of 2023-08-31, Ironwood Pharmaceuticals Inc's institutional ownership level is 63.3%, down from institutional ownership of 66.17% as of 2023-05-31 and down from institutional ownership of 92.78% from a year ago.
Among the most significant stakeholders, the top fund managers owning substantial portions of Ironwood Pharmaceuticals Inc's stock are HOTCHKIS & WILEY (Trades, Portfolio), First Eagle Investment (Trades, Portfolio), and Jefferies Group (Trades, Portfolio), with 0.64%, 0.38%, and 0.21% of shares outstanding respectively.
Earnings: Past and Future
Over the past three years, Ironwood Pharmaceuticals Inc's Ebitda growth averaged 29.4% per year, which is better than 76.45% of 879 companies in the Drug Manufacturers industry. This growth extends to the five-year marker, with a growth of 0%.
Looking forward, the estimated earnings growth for Ironwood Pharmaceuticals Inc is 0% per year, lower than the earnings growth of 36.2% during the past three years. The EPS Growth Rate (Future 3Y to 5Y Estimate) is projected using a combination of historical data and industry trends, factoring in company-specific elements, broader economic conditions, and anticipated market dynamics.
Insider Ownership and Activities
Insider ownership offers insights into the convictions of the company's board directors and C-level employees. Ironwood Pharmaceuticals Inc's insider ownership is approximately 5.94% as of 2023-08-31, compared to insider ownership of 5.77% from a year ago, reflecting the increased faith of those intimately familiar with the company's operations.
Recent insider trades provide a nuanced view of this sentiment. During the past three months, Ironwood Pharmaceuticals Inc had 2 insider sell transactions and 1 insider buy transaction, revealing a complex interplay of insider sentiment towards the company's prospects.
Conclusion
In the ever-evolving realm of stocks, understanding the nuances of ownership and earnings is critical. Ironwood Pharmaceuticals Inc's recent dip is a case study in how major players react to market shifts, and their movements offer crucial insights for potential investors. As always, a holistic view, combining both past performance and future projections, remains key to sound investment decisions.
Screen for stocks with high Insider Cluster Buys using the following page: https://www.gurufocus.com/insider/cluster.
